2017
DOI: 10.24060/2076-3093-2017-7-4-27-31
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of Early Complications After Using Permacol Bioimplant in Combination With Selective Administration of the Nicergolin in Case of Intestinal Fistulas

Abstract: Введение. В современной хирургии кишечные свищи по сей день остаются одной из нерешенных хирургических задач. Если при низких кишечных свищах тактика ве-дения больных условно совпадает у большинства авторов, то наиболее эффективное лечение кишечных свищей высокой локализации остается спорным. В этой связи це-лью работы явилось совершенствование лечения пациентов с несформированными дуоденальными и высокими тонкокишечными свищами путем местного применения коллагенового покрытия с селективным ангиотропным воздей… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 7 publications
0
1
0
Order By: Relevance
“…[ 1 2 ] The feasibility and safety of prescribing drugs for parenteral nutrition are based on the results of clinical studies. [ 3 4 5 6 ] It should be noted that, to date, off-label usage is widely distributed for parenteral nutrition tools, including lipid emulsions. There is a problem to evaluate biological activity in water-soluble substances in all phases of preclinical and clinical studies, so an original solvent for poorly soluble compounds based on substances for parenteral nutrition was developed.…”
Section: Introductionmentioning
confidence: 99%
“…[ 1 2 ] The feasibility and safety of prescribing drugs for parenteral nutrition are based on the results of clinical studies. [ 3 4 5 6 ] It should be noted that, to date, off-label usage is widely distributed for parenteral nutrition tools, including lipid emulsions. There is a problem to evaluate biological activity in water-soluble substances in all phases of preclinical and clinical studies, so an original solvent for poorly soluble compounds based on substances for parenteral nutrition was developed.…”
Section: Introductionmentioning
confidence: 99%